Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor
Launched by ABBVIE · Jan 19, 2022
Trial Information
Current as of July 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of essential tremor in accordance with modified Tremor Investigation Group (TRIG) criteria as described in the protocol.
- • TREDS-Revised Scale (1-4 scale, whole numbers) unilateral score of \>= 3 for the Tremor Disability Scale (TREDS) on any of the 7 unilateral items; no more than a single item score of 1 among the 7 unilateral items in the dominant limb.
- • TETRAS activities of daily living (ADL) (recorded on a 0-4 scale, whole numbers) minimum score of \>= 3 on any of the 5 unilateral items; no more than a single item score of \<=1 among the 5 unilateral items in the dominant limb.
- * At least one of the following criteria must also be met:
- • TETRAS UL score (0-4 scale, with 0.5 increments) of \> 2 in the dominant limb on at least one of the 3 maneuvers OR
- • TETRAS Archimedes spiral task score (0-4 scale, with 0.5 increments) of \> 2 in the dominant limb
- Exclusion Criteria:
- • Any uncontrolled clinically significant medical condition other than the one under study.
- • Any medical condition that may put the participant at increased risk with exposure to BOTOX Purified Neurotoxin Complex.
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hoover, Alabama, United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
Loma Linda, California, United States
Aurora, Colorado, United States
Stamford, Connecticut, United States
Boca Raton, Florida, United States
Fernandina Beach, Florida, United States
Jacksonville Beach, Florida, United States
Port Saint Lucie, Florida, United States
Winter Park, Florida, United States
Atlanta, Georgia, United States
Decatur, Georgia, United States
Kansas City, Kansas, United States
Overland Park, Kansas, United States
Boston, Massachusetts, United States
Burlington, Massachusetts, United States
Jackson, Michigan, United States
Columbia, Missouri, United States
New York, New York, United States
Chapel Hill, North Carolina, United States
Winston Salem, North Carolina, United States
Winston Salem, North Carolina, United States
Centerville, Ohio, United States
New Albany, Ohio, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Charleston, South Carolina, United States
Dallas, Texas, United States
Georgetown, Texas, United States
Houston, Texas, United States
Falls Church, Virginia, United States
Crab Orchard, West Virginia, United States
Marshfield, Wisconsin, United States
Milwaukee, Wisconsin, United States
Vancouver, British Columbia, Canada
Halifax, Nova Scotia, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Westmount, Quebec, Canada
Dallas, Texas, United States
San Antonio, Texas, United States
Montreal, Quebec, Canada
Greenfield, Wisconsin, United States
Jacksonville, Florida, United States
Stamford, Connecticut, United States
Houston, Texas, United States
Boston, Massachusetts, United States
Amherst, New York, United States
Phoenix, Arizona, United States
Orlando, Florida, United States
Burlington, Massachusetts, United States
Winston Salem, North Carolina, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Phoenix, Arizona, United States
Amherst, New York, United States
Patients applied
Trial Officials
ABBVIE INC.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials